JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer

  • 0Center for Soft and Living Matter, Institute for Basic Science (IBS), Ulsan, South Korea.
Cancer Science +

|

March 13, 2024

|

March 13, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study introduces a new method to accurately measure exosomal programmed death-ligand 1 (PD-L1) in urine for metastatic urothelial cancer patients. Normalizing PD-L1 levels using the Alix protein offers a reliable way to monitor treatment response.

Area Of Science

  • Oncology
  • Biomarker Discovery
  • Immunotherapy

Background

  • Metastatic urothelial cancer treatment benefits from anti-programmed death-ligand 1 (PD-L1) therapies.
  • Urinary exosomes show promise as biomarkers for liquid biopsy in urothelial cancer.
  • Urine sample variability necessitates robust normalization methods for exosomal biomarker analysis.

Purpose Of The Study

  • To develop and validate a reliable method for quantifying exosomal PD-L1 in urine.
  • To establish a normalization strategy using Alix for exosomal PD-L1 measurements.
  • To assess the feasibility of monitoring urothelial cancer patients using this novel approach.

Main Methods

  • Extracellular vesicles isolated using ExoDisc, characterized by ExoView for tetraspanins, PD-L1, and Alix.
  • On-disc ELISA employed to measure exosomal PD-L1 and Alix-normalized PD-L1.
  • Analysis of 15 urothelial cancer patients undergoing Tecentriq treatment.

Main Results

  • Alix signal intensity on exosomes was relatively uniform, unlike variable tetraspanin markers.
  • On-disc ELISA demonstrated higher reliability for exosomal PD-L1 detection compared to standard ELISA.
  • Alix-normalized exosomal PD-L1 provided a more consistent measure for patient monitoring.

Conclusions

  • Exosomal Alix serves as a superior normalization factor for urinary PD-L1 quantification in urothelial cancer.
  • This method offers a practical and dependable approach for monitoring treatment response in urothelial cancer patients.
  • The developed technique enhances the utility of urinary exosomes as non-invasive biomarkers for cancer management.

Keywords: